Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ENOCHIAN BIOSCIENCES, INC.

(ENOB)
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/19/2021 10/20/2021 10/21/2021 10/22/2021 10/25/2021 Date
8.94(c) 8.98(c) 8.48(c) 8.28(c) 8.84 Last
267 947 129 289 190 014 194 430 191 683 Volume
-1.11% +0.45% -5.57% -2.36% +6.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2020 - - -
Net income 2020 -11,4 M - -
Net cash position 2020 1,11 M - -
P/E ratio 2020 -17,1x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -26,7 M - -
Net cash position 2021 13,3 M - -
P/E ratio 2021 -8,77x
Yield 2021 -
Capitalization 462 M 462 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 11
Free-Float 38,5%
More Financials
Company
Enochian BioSciences Inc. is a pre-clinical stage biotechnology company. The Company uses its cell, gene and immune therapy technologies for the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, as well as to provide cancer remission in some of the deadliest cancers. The Company’s product candidates include ENOB-HV-01, an autologous transplant with... 
More about the company
All news about ENOCHIAN BIOSCIENCES, INC.
10/19Enochian Biosciences, Inc. Announces Potential Cure for IV Successfully Completes Pre-I..
CI
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
PU
10/18ENOCHIAN BIOSCIENCES : Completes FDA Pre-IND for HIV Antiviral Therapy; Shares Down in Pre..
MT
10/18Enochian BioSciences Completes Pre-IND After FDA Comments
DJ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 month
AQ
10/18ENOCHIAN BIOSCIENCES ANNOUNCES THE S : The Second Pre-IND in 1 Month
CI
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due to Conflict with Respo..
PU
10/15ENOCHIAN BIOSCIENCES : Scientific Advisory Board Member Resigns Due to Conflict with Respo..
AQ
10/15Enochian Biosciences, Inc. Announces Resignation of Peter Piot as Chairperson of the Re..
CI
10/12ENOCHIAN BIOSCIENCES : Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C..
PU
10/12ENOCHIAN BIOSCIENCES : Fireside Chat with Enochian BioSciences' CEO, Dr. Mark Dybul at H.C..
AQ
09/28ENOCHIAN BIOSCIENCES : Sinks 17%, Trading Volume Doubles Daily Average
MT
09/27ENOCHIAN BIOSCIENCES : Announces Its Successful Completion of FDA Pre-IND for a Potential ..
PU
09/27ENOCHIAN BIOSCIENCES : Says Pre-Investigational New Drug Process Completed for Proposed He..
MT
09/27ENOCHIAN BIOSCIENCES : Announces Its Successful Completion of FDA Pre-IND for a Potential ..
AQ
More news
News in other languages on ENOCHIAN BIOSCIENCES, INC.
10/18Enochian Biosciences achève le processus de pré-IND de la FDA pour une thérapie antivir..
09/28Enochian Biosciences chute de 17%, le volume des transactions double la moyenne quotidi..
05/14Enochian BioSciences kondigt een wetenschappelijke presentatie aan van een persoon met ..
More news
Chart ENOCHIAN BIOSCIENCES, INC.
Duration : Period :
Enochian Biosciences, Inc. Technical Analysis Chart | ENOB | US29350E1047 | MarketScreener
Technical analysis trends ENOCHIAN BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Managers and Directors
Mark Richard Dybul Executive Vice Chairman & Chief Executive Officer
Luisa Puche Chief Financial Officer
Rene Sindlev Chairman
Joseph R. Cohen Director-Research & Discovery
Carl Sandler Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ENOCHIAN BIOSCIENCES, INC.180.68%432
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.08%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610